On March 16 OPERON took the firm decision to halt its ongoing R&D projects and to focus all its resources and efforts on finding diagnostic solutions that would help contribute to the detection of SARS-CoV-2.

Having the great advantage of being a company with a wide and proven experience in the diagnostic sector, we began to work hard in developing rapid tests for detection of antibodies and antigens and also in the development of RT-PCR tests for the detection of COVID-19.

As a contribution to this effort, on May 8, the approved subsidies were published for projects to deal with the emergency declared by the COVID-19 disease, by the General Directorate of the Center for Industrial Technological Development (CDTI), being OPERON one of the companies to which part of this grant has been awarded. CDTI is a Public Business Entity, dependent on the Ministry of Science and Innovation, which promotes innovation and technological development of Spanish companies.

Through this web page, we would like to express our gratitude for having been chosen to receive the mentioned grant, with the hope and commitment to continue contributing with our products and services to improve the early diagnosis of the disease, thus responding affectively to the epidemic.

Amount of financing: 499,928 €.

Location: Cuarte de Huerva.

Implementation period: from March 1st, 2020 to August 31th, 2021.

Do you like this article?

Share on Facebook
Share on Twitter
Share on Linkedin
Share on Pinterest

You may also be interested in